Autolus Therapeutics plc (NASDAQ:AUTL) Receives $9.32 Average PT from Brokerages

Autolus Therapeutics plc (NASDAQ:AUTL) has been assigned an average rating of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $9.32.

AUTL has been the subject of several research analyst reports. Truist Financial dropped their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Finally, Wells Fargo & Company decreased their price target on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday, March 21st.

Autolus Therapeutics Price Performance

Autolus Therapeutics stock opened at $1.43 on Tuesday. Autolus Therapeutics has a 52-week low of $1.11 and a 52-week high of $5.25. The stock has a fifty day moving average price of $1.70 and a two-hundred day moving average price of $2.57. The firm has a market capitalization of $380.51 million, a P/E ratio of -1.18 and a beta of 2.06.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $2.98 million. On average, equities research analysts predict that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new position in Autolus Therapeutics during the fourth quarter worth about $26,000. Barclays PLC boosted its stake in Autolus Therapeutics by 1,094.3% during the 4th quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after acquiring an additional 10,866 shares during the last quarter. Dumont & Blake Investment Advisors LLC acquired a new position in Autolus Therapeutics during the fourth quarter valued at approximately $35,000. Arkadios Wealth Advisors bought a new stake in Autolus Therapeutics in the fourth quarter valued at approximately $47,000. Finally, Daiwa Securities Group Inc. raised its holdings in Autolus Therapeutics by 55.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock worth $56,000 after purchasing an additional 8,479 shares during the period. 72.83% of the stock is owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.